Mayne Pharma Group Ltd (ASX:MYX)
A$ 4.78 0.11 (2.36%) Market Cap: 388.36 Mil Enterprise Value: 277.90 Mil PE Ratio: 0 PB Ratio: 0.86 GF Score: 72/100

Full Year 2024 Mayne Pharma Group Ltd Earnings Call Transcript

Aug 22, 2024 / 11:30PM GMT
Release Date Price: A$3.94 (-0.25%)
Shawn O;Brien
Mayne Pharma Group Ltd - Chief Executive Officer, Managing Director, Executive Director

' -

Thank you, operator, and thank you all for joining. My name is Shawn Patrick O'Brien and I am the CEO and Managing Director of Mayne Pharma. We are here to present our financial results for the 12 months ended June 30, 2024, namely FY24. Joining me on this call this morning is Mayne Pharma's CFO, Aaron Grey.

On slide 2 is an important disclaimer. Today's presentation contains forward looking statements and non-IFRS financial measures, which I draw your attention to. All dollar amounts presented today are in AUD unless otherwise noted.

Now turning to our operating metrics on slide 3. I'm delighted to announce today that in FY24, Mayne Pharma has achieved 100% of our key operating metrics or goals we set for ourselves during the financial year and we're previously communicated to the market at the start of FY24.

There were five key pillars underpinning this performance, namely deliver positive direct contribution in all three segments, return the company to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot